ArticleFrontiers in immunology2020
Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 129 citations in OpenAlex.
- An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA.JCI insight · 2024Trial
- IgA binding characteristics of golden hamster and ferret Fcα receptors.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Enhancing immune protection in dairy cattle: role ofmSphere · 2026Article
- Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.iScience · 2026Article
- XBB 1.5 monovalent booster vaccination stimulates oral mucosal and systemic immune responses in healthy adults.Vaccine · 2026Article
- Building better antibody responses: The interplay of infection, vaccination, and immune imprinting.PNAS nexus · 2026Review
- Intranasal Replicating Adenovirus type 4-SARS-CoV-2 Recombinants Induce Superior Immune Response Durability and Efficacy in Preclinical Testing Compared to Standard Intramuscular Vaccines.bioRxiv : the preprint server for biology · 2026Article
- Intranasal administration of spike-specific mRNA-LNP confers more protection than the intramuscular route against SARS-CoV-2.Iranian journal of basic medical sciences · 2026Article
- Early rise in nasal secretory IgA associated with shorter duration of SARS-CoV-2 virus shedding in an acute infection cohort.Frontiers in immunology · 2026Article
- Kinetics of anti-SARS-CoV-2 IgG in saliva and serum post infection, and subsequent vaccination in South Africa.African journal of laboratory medicine · 2026Article
- Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants.Journal of virology · 2025Article
- Eliminating interactions with the viral Fc receptor improves antibody-mediated protection against neonatal HSV infection in mice.Science translational medicine · 2025Article
- BNT162b2 vaccine induces potent SARS-CoV-2 neutralising immunoglobulins in lung mucosa.ERJ open research · 2025Article
- Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity.PLoS pathogens · 2025Article
- Functional and phenotypic profiles of HLA-specific antibodies in relation to antibody-mediated kidney transplant rejection.Human immunology · 2025Article
- Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant.Science advances · 2025Article
- Vaginal microbiome dysbiosis and sexually transmitted infections correlate with concentrations of immunoglobulin isotypes in human cervicovaginal mucus: insights into HIV-1 transmission.Frontiers in immunology · 2025Article
- Impaired mucosal IgA response in patients with severe COVID-19.Emerging microbes & infections · 2024Article
- Article
- SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity.Science translational medicine · 2024Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Understanding humoral immune responses to SARS-CoV-2 infection will play a critical role in the development of vaccines and antibody-based interventions. We report systemic and mucosal antibody responses in convalescent individuals who experienced varying severity of disease. Whereas assessment of neutralization and antibody-mediated effector functions revealed polyfunctional antibody responses in serum, only robust neutralization and phagocytosis were apparent in nasal wash samples. Serum neutralization and effector functions correlated with systemic SARS-CoV-2-specific IgG response magnitude, while mucosal neutralization was associated with nasal SARS-CoV-2-specific IgA. Antibody depletion experiments support the mechanistic relevance of these correlations. Associations between nasal IgA responses, virus neutralization at the mucosa, and less severe disease suggest the importance of assessing mucosal immunity in larger natural infection cohorts. Further characterization of antibody responses at the portal of entry may define their ability to contribute to protection from infection or reduced risk of hospitalization, informing public health assessment strategies and vaccine development efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.